A local autocrine/paracrine role for progesterone is an absolute requirement for corpus luteum formation in primates. Despite this, the mechanism(s) remain obscure, although existing data suggest an anti-apoptotic action to be central. There are a limited number of progestin-regulated gene targets identified in the luteinizing primate follicle, suggesting that a small number of important genes may mediate progesterone action. Possible gene targets could be the epidermal growth factor (EGF) family members amphiregulin (AREG) and epiregulin (EREG). Using macaques undergoing controlled ovarian stimulation cycles, we show that the phosphorylation of EGF receptor (EGFR), ERK 1/2, and AKT increases 6 h after an ovulatory human chorionic gonadotropin (hCG) stimulus and remains activate through 24 h. Immunoreactive EREG and AREG ligands in the follicular fluid both increased in a time frame commensurate with EGFR phosphorylation. The mRNA expression of AREG and EREG in nonluteinized granulosa cells (NLGC) was induced in culture with hCG, an effect blocked by progesterone receptor (PGR) antagonists. Overexpression of PGR B in NLGC and treatment with a nonmetabolizable progestin did not increase either gene, indicating both progesterone and luteinizing hormone/CG are necessary. Addition of EGF and EGF-like ligands did not promote steroidogenesis in vitro by granulosa cells in the presence of gonadotropin, but were able to partially reverse RU486-induced cell death. These data suggest that progesterone promotes the expression of AREG and EREG, which in turn maintain viability of luteinizing granulosa cells, representing one possible mechanism whereby progesterone promotes corpus luteum formation in the primate.
INTRODUCTION
The mid-cycle surge of luteinizing hormone (LH) initiates a series of events culminating in ovulation and differentiation of the follicle into a corpus luteum. During this period, there is a rapid and dramatic increase in progesterone synthesis and dynamic changes in the expression of genes associated with steroidogenesis, proteolysis, angiogenesis, and growth factors such as the epidermal growth factor (EGF)-like ligands amphiregulin (AREG) and epiregulin (EREG) [1] [2] [3] [4] [5] [6] . However, little is known about the coordination of intrafollicular events through autocrine/paracrine mechanisms.
Local progesterone action is a requirement for ovulation and luteal development [3, 7] . While some data suggest that progesterone promotes follicle rupture through the induction of proteases [4, 8, 9] , the role of progesterone as a potent survival factor has been much more clearly demonstrated [10] [11] [12] [13] [14] [15] . Progesterone receptor (PGR) antagonists induce caspase activation, DNA fragmentation, and cell death in luteinizing granulosa cells [10, 14, 15] . In contrast, Peluso et al. [11] [12] [13] 16] have implicated progesterone receptor membrane component 1 (PGRMC1) as important for progesterone's pro-cell survival function, although Friberg et al. [10] demonstrated that immunoneutralization of PGRMC1 had no effect on cultured rat granulosa cell survival. Progesterone may also promote de novo cholesterol synthesis, decrease SUMO-1 expression, and reduce the expression of apoptotic genes [10, 17] . Additionally, PGR À/À mice have normal induction but rapid decline in human chorionic gonadotropin (hCG)-mediated expression of amphiregulin (AREG) and epiregulin (EREG) [18] . Further, an ovulatory hCG bolus given to rhesus monkeys undergoing controlled ovarian stimulation (COS) induces AREG and EREG in a temporal profile coincident with progesterone [19] . Thus, it is likely that progesterone promotes granulosa cell survival through multiple mechanisms, including the induction of EGF family members.
The cAMP-dependent protein kinase A (PKA) is also an important mediator of LH/CG action on luteinizing granulosa cells, in part by promoting the expression of many genes involved in periovulatory events, including progesterone synthesis and PGR expression [20] [21] [22] . Signaling through the cAMP response element binding (CREB) transcription factor is essential to induce AREG expression [23, 24] .
The EGF family consists of 11 known ligands and four receptors (reviewed in [25] ). EGFs are widely expressed throughout the body and have diverse roles such as promoting cell proliferation, survival, and differentiation [25, 26] . In the ovary, AREG and EREG may mediate the effects of an ovulatory stimulus on cumulus cells [6, 27] . However, recent data show that human cumulus cells express functional and physiologically relevant levels of LH receptor, possibly obviating the need for paracrine EGF signaling [28] . Given that mural granulosa cells express high levels of EGF receptor (ERBB1) mRNA and protein [19, 29] , the paracrine/autocrine actions of mural-derived EGF-like ligands need to be addressed. It is hypothesized that progesterone regulates the expression of AREG and EREG in luteinizing primate granulosa cells, which in turn act as a potent cell survival signal, thus providing a potential key link between physiologic observations of progesterone action and cellular mechanisms.
MATERIALS AND METHODS

Reagents
Recombinant EGF-like ligands AREG (cat # 262-AR) and EREG (1195-EP) along with AREG Duoset ELISA development kit (cat # DY262) were obtained from R&D Systems, and native EGF (cat # E4269) was obtained from Sigma. Antibodies against AREG were from Abcam (cat # ab31344; used at 5 lg/ml dilution); EREG (cat # sc-80029; used at 1 lg/ml) and progesterone receptor (cat # sc-539; used at 1 lg/ml) were from Santa Cruz. Horseradish peroxidase-conjugated secondary antibodies against rabbit and mouse IgG were obtained from Jackson Immuno. Human follicle-stimulating hormone (FSH) and CG for in vitro use were obtained from Sigma-Aldrich. RU486 (mifepristone; cat # 475838) was from Calbiochem, and R5020 was from Perkin Elmer. Progesterone receptor antagonist Org 31710 was kindly provided by NV Organon. Signaling inhibitors AG1478 (cat # 658552; Calbiochem), U0126 (cat # V1121; Promega), H89 (cat # 9844; Cell Signaling Tech), and LY294002 (cat # 9901; Cell Signaling Tech) were used. Recombinat human Fas ligand was from Axxora.
Animals
Adult female rhesus macaques were housed at the California National Primate Research Center as described previously [30] . After the onset of menstruation, COS protocols were initiated and granulosa cells collected and processed as previously reported [31] . Briefly, adult female rhesus macaques were monitored daily for the onset of menstruation, after which they were treated with recombinant human FSH (r-hFSH; 37.5 IU, i.m., twice daily; AresSerono or Organon) for 7 days. The GnRH antagonist Antide (5 mg/kg body weight, s.c., single injection daily; Ares-Serono) was administered daily to prevent endogenous gonadotropin secretion. Follicles were aspirated the morning after the last dose of r-hFSH by an ultrasound-guided procedure as described previously [30] . The resulting cells are referred to as nonluteinized granulosa cells (NLGCs). A subset of animals received an ovulatory bolus of rhCG (1000 IU, sc; Ares-Serono) on the morning of Day 8, and follicles were aspirated before (0 h) or 3, 6, 12, and 24 h after hCG (n !3 per time point). The aspirated cells were processed as previously reported [31] . All animal procedures were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the University of California Davis and the University of Maryland Baltimore animal care and use committees.
Cell Culture and Treatments
NLGCs were cultured and in vitro luteinization was induced as reported before [31] . Cells were plated with a seeding density of 2 3 10 5 viable cells per well in 24-well fibronectin-coated plates (Biocoat; BD Biosciences) in 0.4 ml Dulbecco modified Eagle medium (DMEM)/Ham F-12 medium supplemented with penicillin/streptomycin (50 U/ml) and 25 ng/ml hFSH with 20 IU/ml hCG to induce luteinization and incubated at 378C in 5% CO 2 cell culture incubator. NLGCs cultured under similar conditions but without hCG served as controls. In experiments to determine the regulation of AREG and EREG mRNA expression, treatment groups included FSH or FSH þ hCG in the presence or absence of the PKA inhibitor H89 (10 lM) or the PGR antagonists RU486 (2.5 lM) or Org31710 (0-1.0 lM). Equivalent quantities of vehicle (dimethyl sulfoxide) were added to control wells and did not exceed 0.1% v/v. For GC survival experiments, RU486 was used at 50 lM as reported before to induce GC cell death [15] . Equimolar concentrations of different EGF-like ligands were used as indicated in the figure legends in order to compensate for their differences in molecular weight. To determine the signaling mediators involved in EGF-mediated GC survival, EGFR inhibitor AG1478 (10 lM), MEK inhibitor U0126 (10 lM), or AKT inhibitor LY294002 (25 lM) was used at concentrations as reported [32] .
Adenoviral Transduction
Adenoviral vectors expressing recombinant human progesterone receptor (PGR) B isoform used in this study were kindly donated by Dr. Dean Edwards (Baylor College of Medicine), and an empty recombinant adenovirus (AdControl) was used to control the effects of transduction. NLGCs were plated in FSH þ 0.53 ITS in DMEM/Ham F12 overnight, and the following morning media were replaced and cells transduced with Ad-Control or Ad-hPGRB at 3.0 MOI (multiplicity of infection) each in media containing FSH þ 0.53 ITS þ 2.5 lg/ml polybrene (Sigma) for 24 h. Media were refreshed and treatments added as per the experiment.
RT-PCR
Total RNA was extracted using RNaqueous Micro-RNA isolation kit (cat # AM 1931; Applied Biosystems) and reverse transcribed with Moloney murine leukemia virus reverse transcriptase (Invitrogen). Real-Time RT-PCR by TaqMan method was performed for progesterone receptor (PGR; Hs01556707_m1; Applied Biosystems Assay-on-Demand), AREG (Hs00155832_m1), and EREG (Hs00154995_m1), and carboxy-(VIC)-labeled probe was performed for the endogenous control ribosomal protein L19 (RPL19) [19] , which was synthesized by Applied Biosystems and used in the same reaction. Real-Time RT-PCR was carried out as per the manufacturer's recommendation and as previously reported [19] . For relative quantification of mRNA levels, a standard curve was generated using a pool of previously validated cDNA prepared from luteinized GCs. The target gene was normalized to RPL19.
Western Blot
For Western blotting of the follicular fluid, total protein was estimated using the BCA assay (Thermo Scientific) as per the manufacturer's recommended protocol. Follicular fluid volume equivalent to 20 lg total protein was denatured in the presence of a gel loading buffer containing dithiothreitol by heating to 958C for 10 min. Samples were subjected to SDS-PAGE in 4%-20% gradient gels (BioRad Laboratories) and transferred to polyvinylidene fluoride membranes for Western blotting of AREG and EREG. Blots were blocked with 5% milk in Tris-buffered saline containing 0.01% Tween 20 (TBST) for 1 h. Washed blots were incubated with respective secondary antibody conjugated with horseradish peroxidase against the host species IgG from which the primary antibody was made in 5% milk-TBST for an additional 3 h at room temperature. Blots were washed five times with TBST, and were bands visualized using an Amersham ECL Advance chemiluminescence kit (GE Healthcare) on Kodak Gel Logic 440 (Carestream Health). Western blot analysis was performed on follicular fluid from four animals per time point. Western blotting of granulosa cell lysates was performed as previously reported [19] .
Radioimmunoassay
Progesterone levels were determined using commercially available radioimmunoassay (RIA) kits (Siemens Healthcare Diagnostics Inc.). All samples were determined in a single assay, and the within-assay variability was 0.50%.
Amphiregulin ELISA
Amphiregulin ELISA was carried out using an ELISA development kit (cat # DY262; R&D Systems) as per the manufacturer's instructions. Briefly, EIA/ RIA Stripwell flat-bottom polystyrene plates (Corning Inc.) were coated with the AREG capture antibody overnight at room temperature. The plates were then washed and blocked with 1% bovine serum albumin-PBS for 2 h in room temperature. Following washing serially diluted recombinant human AREG standard (2-fold serial dilution and ranged from 1000-31.25 pg/ml), samples were added and incubated for another 2 h. Samples were diluted in the assay buffer to fall within the standard curve, and actual values were extrapolated based on the dilution. Wells were washed, and biotinylated detection antibody was added at the recommended dilution and incubated for additional 2 h. Streptavidin-horseradish peroxidase conjugate was added for 20 min, wells were washed, and the color was developed using a colorimetric substrate for horseradish peroxidase. The A 450 was measured after the reaction was stopped with 1 M sulfuric acid. AREG concentrations in the samples were determined from the standard curve. An EREG ELISA was unable to be validated and so not included in data collection.
Caspase 3/7 Activity Assay
Caspase 3/7 activity was assayed using the SensoLyte Homogeneous AMC Caspase -3/7 Assay Kit (AnaSpec) as per the manufacturer's instructions. Cells were plated in fibronectin-coated black 96-well plates with clear bottom at 50 000 cells per well overnight in FSH þ 0.53 ITS-DMEM/Ham F12. Next PUTTABYATAPPA ET AL. morning, media were changed and treatments added as per the experimental design. After the incubation period, assay reagents were added and incubated on a plate shaker at room temperature for additional 24 h, and the fluorescence of AMC released as a result of caspase action on Ac-DE-VD-AMC substrate was measured using a plate reader at an Ex/Em of 360/460 nm, and data was represented as relative fluorescence unit (RFU) or percent change in RFU from the control treatment.
Statistical Analysis
All data were tested for heterogeneity of variance with the Bartlett chisquare test. Data not normally distributed were transformed to logþ2 before analysis by ANOVA with one repeated measure followed by Bonferroni post tests. Differences were considered significant when P , 0.05. Data for steroid measurements are presented as the percentage of FSH controls in order to normalize variability between individual nonhuman primates. All data are presented as mean 6 SEM from three to four samples unless otherwise stated.
RESULTS
EGF-Like Ligands in the Follicular Fluid
The mRNA expression of betacellulin (BTC), AREG, EREG, and EGFR (ERBB1) in granulosa cells before and after ovulatory stimulus to rhesus macaques undergoing COS protocol was reported previously [19] . For the current study, the expression of the remaining members of the EGF family was determined (Fig. 1) . The mRNA expression of ERBB2 was reduced 4-fold (P , 0.05) by 3 and 6 h post-hCG, and the receptors ERBB3 and 4 were detectable in all samples but did not change before or after administration of hCG (Fig. 1, A-C) . Epithelial mitogen (Epigen; EPGN), heparin-binding EGF (HBEGF), and neuregulin (NRG4) mRNA were expressed in all samples but did not change, and NRG2 was reduced significantly (P , 0.05) 24 h post-hCG (Fig. 1, D-G) . The mRNAs for EGF, transforming growth factor alpha (TGFA), NRG1, and NRG3 were not detectable. The primers-probes used for this real-time PCR assay were validated with positive control cDNA: MCF7 for EGF, PC3 prostate cancer cell line for TGFA, and MDA-MB231 for NRG1 and 3 [33] [34] [35] (data not presented).
Since only AREG and EREG are induced in primates following hCG administration ( [19] and Fig. 1 ), we measured the levels of these two ligands in the follicular fluid by Western blotting. The first apparent increase in AREG and EREG PROGESTERONE REGULATION OF EGF-LIKE LIGANDS occurred 3 and 6 h post-hCG administration, respectively ( Fig.  2A) . A similar gel run parallel to the one used for immunoblotting was stained with Coomassie blue to verify equal protein loading. Follicular fluid concentrations of AREG doubled between 0 and 12 h (from 25.1 6 6.2 to 62.7 6 9.9 ng/ml) and increased further at 24 h (124.4 6 21.5 ng/ml; Fig.  2B ).
AREG and EREG mRNA Expression Profile During In Vitro Luteinization
Treatment of NLGCs (0 h) with hCG in vitro resulted in a significant (P , 0.05) increase in AREG expression at 6 and 24 h, and EREG mRNA was significantly higher only at 6 h (Fig.  2, C and D) . AREG in the culture media collected from the above experiment was undetectable in the media following FSH treatment for 6 and 24 h, but increased to 1.2 6 0.4 and 7.3 6 1.1 ng/ml (P , 0.05), respectively, following hCG addition (Fig. 2E) . The media levels of AREG at 24 h were about 16-18 times less than those in follicular fluid 24 h posthCG in vivo (Fig. 2B vs. Fig. 2E ).
ERBB1 Signaling Profile During Luteinization In Vivo
Activation of ERBB1, AKT, and ERK1/2 in granulosa cells before or after hCG administration to monkeys undergoing COS was assessed by immunoblotting. The phosphorylation of ERBB1, AKT, and ERK1/2 increased 6-12 h post-hCG and was maintained through 24 h (Fig. 3) . Interestingly, the phosphorylation status is similar to the Western blot and secretion profile of AREG and EREG in the follicular fluid (Fig. 2, A and B) .
Regulation of AREG and EREG mRNA Expression
Effect of PKA inhibition. LH/hCG mediate their signals in part through cAMP-PKA-dependent mechanisms. Using the pharmacological inhibitor H89 that specifically blocks cAMPdependent PKA activity, we tested if PKA is important for the expression of AREG and EREG. Treatment of NLGCs in culture with FSH þ hCG induced the expression of both AREG and EREG compared to FSH alone, while addition of H89 in the presence of FSH þ hCG attenuated the induction of both genes ( Fig. 4A; P , 0.05) . 
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Regulation by progesterone/progesterone receptor. PGR mRNA and progesterone synthesis are also dependent upon PKA activity [36] , so that PKA inhibition raises the possibility that AREG and EREG are mediated by progesterone rather than directly by PKA. This was tested using two different PGR antagonists, RU486 and Org31710. RU486 blocked hCGinduced AREG and EREG expression at 6 h (Fig. 4B) . Because RU486 also has anti-glucocorticoid activity, a second PGR antagonist, Org31710, was tested [15] . Org31710 dosedependently attenuated hCG induction of EREG mRNA (P , 0.05), while AREG mRNA expression tended (P ¼ 0.1) to be reduced (Fig. 4C) . In order to determine if progesterone alone regulates AREG or EREG expression or if PKA is coordinately required, NLGCs were infected with an adenovirus expressing PGR-B, since macaque luteal cells predominantly express this form of PGR [37] . Both PGR-B protein and mRNA (Fig. 5A) were detectable at high levels in cells transduced with adenovirus expressing PGR-B compared to control adenovirus (Ad Control) and those maintained in the presence of H89. Over-expression of PGR-B with or without the nonmetabolizable progestin R5020 during FSH treatment had no effect on the basal expression of AREG or EREG, nor did the expression increase beyond the levels induced by FSH þ hCG (Fig. 5, B and C). Additionally, overexpression of PGR-B during FSH þ hCG þ H89 treatment did not restore the mRNA expression of AREG and EREG to that seen with FSH þ hCG (Fig. 5, B and  C) .
Effect of PGR antagonist treatment on maintenance of mRNA expression. In order to determine if progesterone is required for the maintenance of hCG-induced mRNA expression of AREG and EREG as opposed to the initiation of expression, NLGCs were treated for 6, 12, 18, or 21 h with FSH þ hCG, and then media were removed and replaced with media containing FSH þ hCG þ RU486 for the remaining balance of the duration up to 24 h. NLGCs treated with FSH and FSH þ hCG 6 RU486 for the entire 24 h were used as controls. The expression of both AREG and EREG mRNA was reduced when the initial induction was allowed for 6, 12, or 18 h relative to controls (Fig. 5, D and E). RU486 treatment for only the last 3 h of FSH þ hCG (21-24 h) did not affect the expression of either gene (Fig. 5,  D and E) . 
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Function of EGF-Like Ligands in Luteinizing Mural Granulosa Cells
Effect of different EGF-like ligands on steroidogenesis. To test a possible function of EGF-like ligands on mural granulosa cells, NLGCs were cultured for 24 h in the presence of FSH 6 hCG with or without 3 nM concentration of AREG, EREG, or EGF in the presence or absence of the EGFR inhibitor AG1478 (note low endogenous AREG levels in vitro, Fig. 2E ). Treatment with hCG increased progesterone production relative to FSH (12-fold; P , 0.05; Fig. 6A ), while the presence of different EGF-like ligands with FSH or FSH þ hCG had no effect on progesterone production (Fig. 6A) , nor did AG1478 have effects during any condition. AREG and EGF, but not EREG, promoted tritiated thymidine incorporation during FSH treatment, while none of the tested ligands increased proliferation following hCG (Supplemental Fig. S1 ; all Supplemental Data are available online at www.biolreprod. org).
FIG. 5.
Role of progesterone receptor in expression of AREG and EREG mRNA during luteinization. NLGCs were transduced with control (Ad-control) or PGR-B containing adenoviral vectors (Ad-PGR-B) overnight, and cells were subsequently treated with FSH 6 hCG with or without H89 or RU486 6 the nonmetabolizable progestin R5020 for 24 h. Transduction efficacy was determined by measuring PGR mRNA levels using real-time RT-PCR (A). The inset of A represents a Western blot for PGR-B (PR-B) following transduction of NLGCs with Ad-control or Ad-PGR-B; the blot was stripped and reprobed for GAPDH. AREG (B) and EREG (C) mRNA levels were measured by real-time RT-PCR. To determine the role of progesterone in maintaining mRNA expression of AREG and EREG during luteinization, NLGCs were treated with FSH or FSH þ hCG, and RU486 (2.5 lM) was added 6, 12, 18, or 21 h after hCG; the expression of AREG (D) and EREG (E) was determined 24 h after the addition of hCG. Data are presented as mean 6 SEM (n ¼ 3). Different superscript letters indicate significant differences between treatments.
PUTTABYATAPPA ET AL.
Effect of EGF-like ligands on PGR antagonist-induced cell death. In order to test the hypothesis that AREG and EREG can reduce RU486-induced apoptosis, AREG, EREG, or EGF were added in increasing equimolar concentrations (30, 150 , or 300 nM) along with FSH þ hCG þ RU486. RU486 reduced luteinizing granulosa cell viability by 70% relative to controls (P , 0.05; Fig. 6B ), while 150 and 300 nM of each ligand significantly increased (P , 0.05) viability relative to RU486 alone (Fig. 6B) . As a corollary to viability, caspase 3/7 activity was used as a measure of apoptosis, and because AREG, EREG, and EGF showed similar effects on viability in Figure 6B , only EGF was used. RU486 increased caspase 3/7 activity, and EGF reduced RU486-induced caspase 3/7 activity in a dose-dependent manner (Fig. 6C) . Since EGF signals through activation of ERK 1/2 and AKT pathways, we examined the effects of the EGFR inhibitor AG1478 (10 lM), the MEK inhibitor U1026 (10 lM), or the AKT inhibitor LY294002 (25 lM) to determine the respective contributions of these pathways to the protection provided by EGFs from RU846-induced cell death. The EGFR inhibitor (AG1478) and AKT inhibitor (LY294002) blocked the ability of EGF to protect cells from RU486, while MEK inhibitor (U0126) did not alter the protective ability of EGF (Fig. 6C) . The ability of EGF to reverse RU486-induced cell death was additionally confirmed using the transformed human granulosa-luteal cell line hGL5, where EGF was able to dose-dependently reverse RU486-induced cell death (Supplemental Fig. S2 ).
Progesterone receptor is induced in granulosa cells following hCG treatment [38] ; therefore, a PGR antagonist is useful only during luteinization. To test if the EGFR pathway has the potential to promote survival in NLGCs as well, killing was induced with Fas Ligand (FasL) [39] . Since FAS is expressed at low levels in the NLGCs [40] , granulosa cells were pretreated with interferon gamma (IFNc) for 48 h in the presence of FSH to induce FAS mRNA (Supplemental Fig. S3A ). INFcsensitized NLGCs were treated with FSH 6 hCG with or without EGF (100 ng/ml) for 3 h. At the end of this 3-h period, FasL was added and the cells incubated for additional 3 h. FasL induced caspase 3/7 activity during FSH and FSH þ hCG treatment, although EGF tended (P ¼ 0.07) to reduce caspase activity only following hCG (Supplemental Fig. S3B ).
DISCUSSION
An ovulatory stimulus induces progesterone synthesis and PGR expression [38, 41] . Progesterone has an autocrine/ paracrine role within the luteinizing follicle and promotes ovulation, granulosa cell survival, and luteinization [42] [43] [44] [45] [46] . While progesterone induction of proteases is suggested to be the mechanism by which it mediates follicle rupture [4, 44] , it is not clear how it maintains luteinizing granulosa cell viability. Recent studies have shown that mRNAs for EGF-like ligands (AREG, EREG) are induced following ovulatory stimulus [6, 19] , and the temporal expression profile of these ligands during the rodent and primate periovulatory interval matches the expression profile of progesterone and PGR [6, 19, 41] . Additionally, AREG and EREG expression in PGR knockout mice (PRKO) increases following hCG, but there is a rapid decline in the mRNA expression of both genes compared to heterozygous animals [18] . These data, therefore, suggest that progesterone may have a role in the regulation of these ligands. AREG and EREG were in turn hypothesized to mediate progesterone's prosurvival actions in luteinizing granulosa cells. In this study, we show that (1) progesterone is required for the expression of both AREG and EREG and (2) luteinizing granulosa cell death induced following PGR antagonist   FIG. 6 . Effect of EGF-like ligands on granulosa steroidogenesis and survival during luteinization in vitro. NLGCs were obtained prior to hCG in rhesus monkeys undergoing COS. A) Cells were treated with equimolar concentrations of different EGF-like ligands (3 nM) in the presence of FSH (nonluteinized condition) or FSH þ hCG (luteinizing condition) with or without EGFR inhibitor AG1478 (20 lM), and after 24 h media levels of progesterone were determined by RIA. B) Granulosa cells were treated with FSH þ hCG with or without RU486 (50 lM) to induced cell death. Additional wells received increasing equimolar concentrations of the AREG, EREG, or EGF (30, 150, 300 nM) in the presence of RU486, and viability was determined after 24 h. C) Cells were treated with FSH þ hCG with or without RU486 and EGF (0-1000 ng/ml). Additional wells were treated with 500 ng/ml EGF in the presence or absence of the EGFR antagonist AG1478 (20 lM), the MEK inhibitor U0126 (10 lM), or the AKT inhibitor LY294002 (50 lM). Cells were harvested after 24 h for caspase 3/7 activity. Relative fluorescence units (RFU) are plotted as percent of change over that for FSH þ hCG-treated cells. Data are presented as mean 6 SEM. Bars with different letters indicate significant differences (P , 0.05; n ¼ 3).
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treatment can be decreased by addition of these ligands. Thus, in the primate luteinizing follicle, progesterone maintains granulosa cell viability at least partly through the induction of anti-apoptotic EGF-like ligands.
We have shown previously that an ovulatory stimulus increases AREG and EREG, but not BTC, expression in primate luteinizing granulosa cells [19] . Data from the present study indicate that AREG and EREG are the only members of the EGF-like ligands that increase in primate granulosa cells following an ovulatory stimulus. In contrast, BTC and epigen also increase in rodents, indicating species specificity in gene regulation [47] . Intrafollicular concentrations of AREG are 120 ng/ml 24 h after an ovulatory bolus, levels that are similar to those measured in follicular fluid obtained from women undergoing IVF [48] . While an EREG ELISA was not technically feasible, data from Western blot analysis suggest similar amounts of AREG and EREG in follicular fluid. However, Peluffo et al. [49] recently reported that while AREG levels in follicular fluid were similar to the current findings, EREG was not consistently detectable. It is not clear why this discrepancy exists, although it is possible that the EREG measured by Western blot in the current study could be crossreacting with AREG or other members of the EGF family. Regardless, data from the current study and previously published reports by Zamah et al. [50] and Peluffo et al. [49] indicate that AREG is critical in periovulatory signaling. In contrast, BTC [19] , HB-EGF, EPGN, and NRG4 mRNAs (from this study) are present before and after hCG but do not change; therefore, it is possible that the total bioactive EGF-like ligands within the luteinizing follicle could be many fold higher than the levels of AREG alone measured in the follicular fluid. Surprisingly, AREG levels are ;12-fold lower in culture media during in vitro luteinization experiments relative to follicular fluid. This could be due to the limited number of cells in culture or an extra-granulosa cell source. Regardless, the low endogenous levels in vitro allow the use of exogenous treatments.
EGF-like ligands signal through binding and activating four types of transmembrane receptor tyrosine kinases found in granulosa cells before and after hCG. The activation status of these different receptor types, heterodimerization, and associations with other receptor types in the ovary remains unknown. However, since both AREG and EREG signal through ERBB1, the phosphorylation of this receptor type was used as a biomarker of overall EGF family activity. The tyrosine residue (Y1086) on ERBB1, which is most commonly phosphorylated after ligand binding, was found to be phosphorylated at low levels prior to hCG but increased substantially beginning 6 h post-hCG. Interestingly, the temporal phosphorylation profile of ERBB1 is similar to immunoreactive levels of AREG and EREG in follicular fluid, suggesting a causal association with these two ligands in particular. ERBB1 in rat granulosa cells is similarly phosphorylated following LH and has been shown to be dependent on EGF-like ligands [29] . Downstream pathways commonly activated by ERBB1 are MAPK-ERK and PKB-AKT pathway [25, 51] , and the phosphorylation of both of these is similar to that of ERBB1, further suggesting that these pathways are activated at least in part by EGF-like ligands. The current data suggest that AREG and EREG activate ERBB1 with downstream activation of ERK and AKT.
LH/hCG-induced increase in AREG and EREG in rat and human granulosa cells occurs through a cAMP-dependent mechanism [29, 52] . PKA inhibition confirms these observations in macaque luteinizing granulosa cells, although PKA inhibition also reduces progesterone and PGR expression. Thus, it is difficult to determine whether AREG/EREG expression is cAMP dependent, progesterone dependent, or both. AREG and EREG are normally induced in PRKO mice following treatment with hCG but decline rapidly compared to wild-type animals, suggesting that these ligands are induced in an hCG-dependent, cAMP-mediated pathway [18] . The rapid decline in expression in PRKO animals suggests further that progesterone/PGR is required to maintain the expression of these genes. Analysis of AREG and EREG promoter using the Web-based MatInspector program [53] revealed multiple cAMP response element (CRE) and progesterone response element (PRE) sites upstream of the transcription start site. Given this, it is not surprising that cAMP-dependent PKA activity is required to induce the expression of these genes [23, 24] , although hCG-induced AREG is only partially attenuated by the PKA inhibitor H89, suggesting that multiple signaling pathways may promote maximal induction of this gene. However, these ligands are also induced in a progesteronedependent manner, although PGR/progesterone alone is insufficient to increase expression. The data suggest that PKA-dependent mechanisms may be responsible for the initial induction of AREG/EREG, while progesterone serves an essential secondary role in maintaining expression. This hypothesis is additionally supported by the fact that RU486 can reduce AREG/EREG mRNA levels even after a period of initial induction, and this clearly is dependent upon the length of exposure to RU486.
While mural granulosa cells synthesize EGF-like ligands in response to hCG, it is not clear what local autocrine/paracrine actions they have on mural granulosa cells. In the present study, AREG and EREG had no effect on granulosa cell progesterone production in the presence of FSH or FSH þ hCG, and AG1478 did not reduce hCG-mediated progesterone production. In primates, therefore, EGF-like ligands do not increase progesterone synthesis above and beyond hCG. EGFs are also powerful mitogens through activation of the ERK pathway [54] . Although hCG increases levels of EGF-like ligands and ERBB1 and ERK phosphorylation, the percentage of granulosa cells in S-phase remains low throughout the periovulatory interval [19] . Further, AREG and EGF (but not EREG) increase 3 H thymidine incorporation in NLGCs in the presence of FSH, but not FSH þ hCG, suggesting that hCGmediated cell cycle arrest cannot be overcome by even very high local concentrations of EGF-like ligands. It remains unclear why EREG is unable to cause cell cycle progression in NLGCs, but it is not due to low bioactivity, as this hormone stock caused phosphorylation of ERBB1 in SKOV3 ovarian cancer cells (Supplemental Fig. S1 ).
Progesterone is a potent luteinizing granulosa cell survival factor. The present study extends these findings to demonstrate that EGF-like ligands partially prevent RU486-induced cell death. In addition, native EGF also reverses the death-inducing effects of RU486 in hGL5 cells. Because progesterone is so essential in maintaining granulosa cell viability, and because RU486 is so efficacious in promoting granulosa cell death, it is likely that very high levels of EGF-like ligands are necessary to overcome RU486-induced cell death and may be reflective of the presumptively high combined concentrations of all EGFs in macaque follicular fluid. In addition to immunoreactive AREG and EREG in follicular fluid, HB-EGF, EPGN, and NRG4 mRNA are expressed by luteinizing granulosa cells. While the mechanism of EGF-like ligands in attenuating cell death is not entirely clear, inhibiting ERBB1 or the AKT (but not ERK) pathway reversed the prosurvival effects of EGF, indicating that ERBB1-dependent AKT activation is likely the pathway used by EGFs to promote granulosa cell survival. AKT can deactivate pro-apoptotic proteins such as BAD and caspase 9 PUTTABYATAPPA ET AL.
by phosphorylation as well as increase pro-survival gene expression by activating transcription factors like NFKB1, HIF1A, and CREB [55] [56] [57] . Progesterone may also operate through a nongenomic mechanism involving the activation of protein kinase G to promote granulosa cell viability [58] . Nevertheless, EGFs are prosurvival factors, and our data further indicate that progesterone regulates their expression in luteinizing macaque granulosa cells. These ligands could, therefore, be ideal candidates for mediating progesterone's prosurvival action in luteinizing granulosa cells.
Because PGR antagonists are only relevant when used following hCG treatment, FasL was used to test if EGFs have survival effects on NLGCs. Granulosa cells require IFNc pretreatment to sensitize them to FasL-induced apoptosis through induction of FAS mRNA [39, 40, 59] . Interestingly, FasL induced caspase 3/7 activity during both FSH and FSH þ hCG treatment, but addition of EGF provides protection only in the presence of FSH þ hCG. Vickers et al. [60] previously showed in INFc-sensitized bovine granulosa cells that EGF, but not FSH or LH, prevents FasL-induced apoptosis. In addition, Porter et al. [61] demonstrated that bovine granulosa cells after an LH surge are resistant to FasL-induced cell death, and addition of protein synthesis inhibitors increases the susceptibility to FasL [62] . These studies support the hypothesis that LH/hCG-and progesterone-induced expression of EGF-like ligands promotes granulosa cell survival. AREG is produced at low concentrations in vitro, which may explain why caspase 3/7 activity is similar between FSH and FSH þ hCG; regardless, EGF was effective in preventing FasLinduced cell death only in the presence of hCG. It is hypothesized that a profound prosurvival factor is required specifically during luteinization as there is rapid loss/ desensitization of LHCGR signaling following an ovulatory stimulus, with a subsequent loss in gonadotropin support and cAMP tone [63, 64] . In addition, due to increased steroidogenesis, there is an increase in oxidative stress that may be detrimental to these cells [65] , necessitating the presence of a prosurvival factor.
Progesterone has been known for years to be a potent survival signal for luteinizing granulosa cells. However, the mechanisms subserving this effect have been exceedingly difficult to determine. In addition, the limited number of authentic progesterone-induced genes during luteinization led to the hypothesis that progesterone exerts its actions through a limited set of target genes. In rhesus macaques undergoing COS protocols, AREG and EREG are both expressed in a progesterone-dependent fashion. Further, ERBB1 is phosphorylated in a manner consistent with the appearance of shed AREG and EREG. Importantly, EGFs provide protection against RU486-induced cell death in luteinizing granulosa cells. The present study, therefore, suggests that at least part of progesterone's survival effects during primate corpus luteum formation is via the induction of EGF-like ligands.
